Intellectus Partners LLC Buys 749 Shares of Novo Nordisk A/S (NYSE:NVO)

Intellectus Partners LLC increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 9.2% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 8,884 shares of the company’s stock after acquiring an additional 749 shares during the quarter. Intellectus Partners LLC’s holdings in Novo Nordisk A/S were worth $1,058,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. 1620 Investment Advisors Inc. bought a new stake in shares of Novo Nordisk A/S during the second quarter worth approximately $25,000. Strategic Investment Solutions Inc. IL bought a new position in shares of Novo Nordisk A/S during the second quarter worth approximately $25,000. Orion Capital Management LLC bought a new stake in Novo Nordisk A/S in the 1st quarter valued at $26,000. Gilliland Jeter Wealth Management LLC boosted its stake in Novo Nordisk A/S by 200.0% in the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after purchasing an additional 120 shares during the period. Finally, Halpern Financial Inc. grew its holdings in Novo Nordisk A/S by 113.0% in the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after buying an additional 113 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 1.5 %

NVO stock opened at $105.35 on Friday. The firm has a 50-day moving average price of $119.68 and a 200-day moving average price of $129.92. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $472.76 billion, a P/E ratio of 34.09, a price-to-earnings-growth ratio of 1.31 and a beta of 0.42.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, BMO Capital Markets cut their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.